B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

(2021) Brad H Rovin et al.   LANCET

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

(2020) Richard Furie et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Type II anti‐CD20 Antibody Obinutuzumab (GA101) is More Effective than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model

(2020) Anthony D. Marinov et al.   Arthritis & Rheumatology

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

(2019) Antonis Fanouriakis et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti‐ CD 20 monoclonal antibody for the desensitization of candidates for renal transplant

(2019) Robert R. Redfield et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia

(2019) Vlatko Pejsa et al.   LEUKEMIA & LYMPHOMA

Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis

(2018) Liliana Michelle Gomez Mendez et al.   Clinical Journal of the American Society of Nephrology

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

(2017) Robert Marcus et al.   NEW ENGLAND JOURNAL OF MEDICINE

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples

(2017) Venkat Reddy et al.   RHEUMATOLOGY

Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis

(2016) Maria G. Tektonidou et al.   Arthritis & Rheumatology

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

(2015) C. L. Freeman et al.   BLOOD

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies

(2015) T. R. W. Tipton et al.   BLOOD

The frequency and outcome of lupus nephritis: results from an international inception cohort study

(2015) John G. Hanly et al.   RHEUMATOLOGY

Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus

(2015) Venkat Reddy et al.   Arthritis & Rheumatology

Predictors of Long-Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro-Lupus Nephritis Cohort

(2015) Maria Dall'Era et al.   Arthritis & Rheumatology

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study

(2013) Eduardo F. Mysler et al.   ARTHRITIS AND RHEUMATISM

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

(2013) S. Herter et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

(2012) Brad H. Rovin et al.   ARTHRITIS AND RHEUMATISM

B-cell depletion in the treatment of lupus nephritis

(2012) Jon W. Gregersen et al.   Nature Reviews Nephrology

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

(2012) Bevra H. Hahn et al.   ARTHRITIS CARE & RESEARCH

B cell biomarkers of rituximab responses in systemic lupus erythematosus

(2011) Edward M. Vital et al.   ARTHRITIS AND RHEUMATISM

An Acquired Defect in IgG-Dependent Phagocytosis Explains the Impairment in Antibody-Mediated Cellular Depletion in Lupus

(2011) A. Ahuja et al.   JOURNAL OF IMMUNOLOGY

Mechanisms of B cell autoimmunity in SLE

(2011) Thomas Dörner et al.   ARTHRITIS RESEARCH & THERAPY

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD